About Cyclin-A2
Cyclin-A2 (CCNA2) is a protein
from Homo sapiens identified by UniProt accession
P20248, 432 residues long.
MolForge cross-references it against 0 known binders and
409 disease associations.
Target properties
| Protein name | Cyclin-A2 |
|---|
| UniProt accession | P20248 |
|---|
| Gene | CCNA2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 432 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (409)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.55
- mean corpuscular volume · score 0.40
- mean corpuscular hemoglobin concentration · score 0.37
- mean corpuscular hemoglobin · score 0.35
- erythrocyte count · score 0.33
- glioblastoma multiforme · score 0.31
- body height · score 0.31
- lung adenocarcinoma · score 0.31
- red blood cell density measurement · score 0.29
- ovarian cancer · score 0.29
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P20248-F1 | alphafold | PREDICTED | 73.07 | — |
Amino-acid sequence (432 residues)
MLGNSAPGPA TREAGSALLA LQQTALQEDQ ENINPEKAAP VQQPRTRAAL AVLKSGNPRG LAQQQRPKTR RVAPLKDLPV NDEHVTVPPW KANSKQPAFT IHVDEAEKEA QKKPAESQKI EREDALAFNS AISLPGPRKP LVPLDYPMDG SFESPHTMDM SIILEDEKPV SVNEVPDYHE DIHTYLREME VKCKPKVGYM KKQPDITNSM RAILVDWLVE VGEEYKLQNE TLHLAVNYID RFLSSMSVLR GKLQLVGTAA MLLASKFEEI YPPEVAEFVY ITDDTYTKKQ VLRMEHLVLK VLTFDLAAPT VNQFLTQYFL HQQPANCKVE SLAMFLGELS LIDADPYLKY LPSVIAGAAF HLALYTVTGQ SWPESLIRKT GYTLESLKPC LMDLHQTYLK APQHAQQSIR EKYKNSKYHG VSLLNPPETL NL
Explore Cyclin-A2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets